Author

L. Lerner

Institution: Keros Therapeutics (United States)

Observed institution: Keros Therapeutics (United States)

OpenAlex ID: A5065733332

RKER-012, A Novel Modified ActRIIB Ligand Trap, Reduced Pulmonary Vascular Pathology in a Rat Model of Pulmonary Arterial Hypertension Through Attenuation of TGFb Family Autocrine/Paracrine Signaling Within the Vasculature

2024 · E. Ledoux, E. Lema, et al. · 1

P33 RKER-065 ameliorated muscle and bone loss in a progressive murine model of Duchenne muscular dystrophy

2023 · R. Nathan, M. Cahill, et al. · Neuromuscular Disorders · 1

Administration of KER-012, a Modified Activin Receptor IIB Ligand Trap, Led to Changes in Biomarkers of Cardiovascular Health in a Ph1 Study Conducted in Healthy Post-Menopausal Women

2023 · H. Natarajan, L. Lerner, et al. · 1

652PRKER-065 improved the therapeutic response to phosphorodiamidate morpholino oligomers (PMO) in a Duchenne muscular dystrophy mouse model

2025 · F. Fisher, G. Zhen, et al. · Neuromuscular Disorders

P34 RKER-065, a novel ActRII ligand trap, counteracted the negative impact of glucocorticoid treatment on bone and muscle

2023 · G. Zhen, R. Nathan, et al. · Neuromuscular Disorders

Works count: 5

Citation count: 3

H-index: 1

I10-index: